[go: up one dir, main page]

PE20180023A1 - METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENT - Google Patents

METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENT

Info

Publication number
PE20180023A1
PE20180023A1 PE2016000848A PE2016000848A PE20180023A1 PE 20180023 A1 PE20180023 A1 PE 20180023A1 PE 2016000848 A PE2016000848 A PE 2016000848A PE 2016000848 A PE2016000848 A PE 2016000848A PE 20180023 A1 PE20180023 A1 PE 20180023A1
Authority
PE
Peru
Prior art keywords
treatment
hsdd
trazodone
bupropion
women
Prior art date
Application number
PE2016000848A
Other languages
Spanish (es)
Inventor
Nick G Sitchon
Robert E Pyke
Robert Taylor Segraves
Anita Clayton
Leonard Derogatis
Molly Katz
Cindy Meston
Original Assignee
S1 Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S1 Biopharma Inc filed Critical S1 Biopharma Inc
Publication of PE20180023A1 publication Critical patent/PE20180023A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a un metodo de tratamiento de una mujer con trastorno del deseo sexual hipoactivo (HSDD) que comprende: a) administracion diaria de un primer farmaco tal como bupropion que tiene una concentracion de dosis de 150 mg; b) administracion diaria de un segundo farmaco tal como trazodona que tiene una concentracion de dosis de 75 mg; y c) dicha administracion del primer y segundo farmaco se encuentra de acuerdo con un regimen de tratamiento prescrito para el tratamiento la mujer para HSDDIt relates to a method of treating a woman with hypoactive sexual desire disorder (HSDD) comprising: a) daily administration of a first drug such as bupropion having a dose concentration of 150 mg; b) daily administration of a second drug such as trazodone having a dose concentration of 75 mg; and c) said administration of the first and second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.

PE2016000848A 2016-06-17 2016-06-20 METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENT PE20180023A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351904P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
PE20180023A1 true PE20180023A1 (en) 2018-01-09

Family

ID=57758862

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000848A PE20180023A1 (en) 2016-06-17 2016-06-20 METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENT

Country Status (9)

Country Link
KR (1) KR20170142797A (en)
AR (2) AR105087A1 (en)
AU (1) AU2016204151A1 (en)
CA (1) CA2933921A1 (en)
CL (1) CL2016001597A1 (en)
MX (1) MX2016008272A (en)
PE (1) PE20180023A1 (en)
UY (1) UY36742A (en)
WO (1) WO2017218018A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897864A (en) * 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
WO2005102342A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
CN106924259A (en) * 2012-08-06 2017-07-07 S1制药有限公司 Therapeutic scheme

Also Published As

Publication number Publication date
WO2017218018A1 (en) 2017-12-21
MX2016008272A (en) 2017-12-18
UY36742A (en) 2016-12-30
CL2016001597A1 (en) 2017-10-06
CA2933921A1 (en) 2017-12-17
AU2016204151A1 (en) 2018-01-18
KR20170142797A (en) 2017-12-28
AR105087A1 (en) 2017-09-06
AR105047A1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
MX2019005379A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof.
MX2021000609A (en) METHODS OF TREATMENT WITH SUBSTRATE DRUGS FOR CYP3A4.
CL2017002996A1 (en) Tetra-substituted alkene compounds and their use
CO2017011536A2 (en) Compositions comprising a combination of a programmed anti-death antibody 1 (pd-1) and another antibody
MX394252B (en) Cancer treatment using combinations of erk and raf inhibitors
ECSP18024971A (en) ADJUNCTIVE THERAPY WITH 25-HYDROXY VITAMIN D AND ITEMS OF THE SAME
PE20142363A1 (en) USES AND MANUFACTURING ARTICLE INCLUDING HER2 PERTUZUMAB DIMERIZATION INHIBITOR
MX2017012982A (en) Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes.
CR20170085A (en) ADJUNCTIVE THERAPY WITH 25-HYDROXY VITAMIN D
MX2019003134A (en) Combination therapy.
MX2017007256A (en) BROMODOMINIUM INHIBITOR AS AN ASSISTANT IN IMMUNOTHERAPY AGAINST CANCER.
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
MX373231B (en) ANTICANCER AGENT.
MX2018008694A (en) METHODS AND COMPOSITIONS TO TREAT HYPERHYDROSIS.
MX2018007933A (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion.
MX2016015437A (en) COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101.
MX2018008078A (en) ANTIBODY-PHARMACO SYNERGISM TECHNOLOGY FOR THE TREATMENT OF DISEASES.
MX2019002047A (en) Methods and compositions for treating cutaneous fungal infections.
MX2020007760A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability.
UY36202A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES RECOMBINANT HEMOGLOBIN OR A THERAPEUTIC AGENT BASED ON SUBUNITIES FOR CANCER TREATMENT
MX2016014307A (en) Aided delivery of plant treatment agents.
MX2018012392A (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative.
CL2017000636A1 (en) Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers
PE20180023A1 (en) METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENT
EA202091743A1 (en) DENDRITIC CELL VACCINATION PARALLEL WITH CHEMOTHERAPY